4
Changes in Ownership
Dyne Therapeutics, Inc. Filed Acc 0001193125-26-223984
Chief Commercial Officer sold 228 shares at $18.36 ($4,186)
- Traded under a Rule 10b5-1 plan
From the SEC's structured data for this filing
Trades in this filing
Table I: Non-derivative
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| Friedl-Naderer Johanna Chief Commercial Officer | 2026-05-13 | Sale 10b5-1 | −228 | $18.36 | $4,186 | 154,353 | D: show line 1 in the form |
| Open-market sales · 228 sh · avg $18.36 · $4,186 | |||||||
Loading xslF345X06/ownership.xml…